Capsule Summary Slidesets

Share

Program Content

Activities

  • STIMULUS-AML2
    STIMULUS-AML2: Preliminary Safety of Sabatolimab Monotherapy in Patients With MRD+ AML After AlloSCT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2023

  • COMMANDS Full Analysis
    COMMANDS: Full Analysis of Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2023

  • IMerge Subgroup Analysis
    Phase III IMerge Subgroup Analysis: Imetelstat for Achieving Transfusion Independence in ESA R/R or Ineligible Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

  • Retrospective STOP-VEN Study
    STOP-VEN: Discontinuation of Venetoclax + Azacitidine for Patients With AML in Remission at Time of Treatment Interruption
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

  • Quizartinib, Ven, Dec in FLT3 ITD Mutated AML
    Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • Oral AAA in ND APL
    All-Oral Arsenic Trioxide–Based Induction in Newly Diagnosed Acute Promyelocytic Leukemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • ASCEND-CML
    ASCEND-CML: Phase II Trial of Frontline Asciminib in Patients With CP-CML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • Revumenib for Acute Leukemia
    AUGMENT-101: Phase II Study of Revumenib for R/R KMT2Ar Acute Leukemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • QuANTUM-First  MRD Analysis
    Phase III QuANTUM-First: Prognostic Value of FLT3-ITD–Specific MRD Clearance at Induction/Consolidation Using Chemotherapy With or Without Quizartinib in Patients With AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.